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Endocannabinoids Regulate Growth and Survival
of Human Eccrine Sweat Gland–Derived
Epithelial Cells
Gabriella Czifra1, Attila G. Szo¨ll +osi1, Bala´zs I. To´th1, Julien Demaude2, Charbel Bouez2,
Lionel Breton2 and Tama´s Bı´ro´1
The functional existence of the emerging endocannabinoid system (ECS), one of the new neuroendocrine
players in cutaneous biology, is recently described in the human skin. In this study, using human eccrine sweat
gland–derived immortalized NCL-SG3 model cells and a wide array of cellular and molecular assays, we
investigated the effects of prototypic endocannabinoids (anandamide, 2-arachidonoylglycerol) on cellular
functions. We show here that both endocannabinoids dose-dependently suppressed proliferation, induced
apoptosis, altered expressions of various cytoskeleton proteins (e.g., cytokeratins), and upregulated lipid
synthesis. Interestingly, as revealed by specific agonists and antagonists as well as by RNA interference, neither
the metabotropic cannabinoid receptors (CB) nor the ‘‘ionotropic’’ CB transient receptor potential ion channels,
expressed by these cells, mediated the cellular actions of the endocannabinoids. However, the endocanna-
binoids selectively activated the mitogen-activated protein kinase signaling pathway. Finally, other elements
of the ECS (i.e., enzymes involved in the synthesis and degradation of endocannabinoids) were also identified
on NCL-SG3 cells. These results collectively suggest that cannabinoids exert a profound regulatory role in
the biology of the appendage. Therefore, from a therapeutic point of view, upregulation of endocannabinoid
levels might help to manage certain sweat gland–derived disorders (e.g., tumors) characterized by unwanted
growth.
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INTRODUCTION
Recent bodies of evidence implicate that the endocannabi-
noid system (ECS) (Pacher et al., 2006; Di Marzo, 2008;
Pertwee et al., 2010), as one of the new players in cutaneous
neuroendocrinology (Slominski and Wortsman, 2000; Slo-
minski et al., 2008), may play a significant role in controlling
skin homeostasis (Bı´ro´ et al., 2009). Endocannabinoids such
as anandamide (N-arachidonoylethanolamine, AEA) and 2-
arachidonoylglycerol (2-AG) (Calignano et al., 1998; Karsak
et al., 2007), enzymes involved in the synthesis and
metabolism of these lipid mediators (Berdyshev et al., 2000;
Maccarrone et al., 2003), as well as cannabinoid receptors
(CB), were all identified on various skin cell populations
(Casanova et al., 2003; Ibrahim et al., 2005; Stander et al.,
2005; Blazquez et al., 2006; Karsak et al., 2007; Telek et al.,
2007; Dobrosi et al., 2008; To´th et al., 2011).
Of further importance, the cutaneous ECS was shown to
regulate the well-balanced growth and differentiation program
of skin cells. Namely, AEA was reported to inhibit the
differentiation of cultured human epidermal keratinocytes
(Maccarrone et al., 2003; Paradisi et al., 2008), whereas we
have recently shown that AEA suppressed growth and induced
apoptosis of these cells (To´th et al., 2011). Likewise, we have
also presented that the locally produced AEA inhibited in vitro
hair shaft elongation and induced apoptosis-driven premature
catagen regression (Telek et al., 2007). Of further importance,
using a human sebaceous gland–derived cultured sebocyte
model, we have demonstrated that endocannabinoids (AEA
and 2-AG), produced by these cells, constitutively enhanced
lipid production and induced chiefly apoptosis-driven cell
death (hallmarks of sebocyte differentiation and hence a model
of holocrine sebum production) (Dobrosi et al., 2008).
Interestingly, although the in situ expressions of both CB1
and CB2 have been described on epithelial cells of
human eccrine sweat glands (Stander et al., 2005), we lack
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functional data on the role of endocannabinoids in the
regulation of biology of the smallest appendage of the
mammalian skin. Therefore, in this study, we aimed at
defining the effects of the most extensively studied endocan-
nabinoids (i.e., AEA and 2-AG) on growth and survival of
human eccrine sweat gland cells. By using cultured NCL-SG3
eccrine sweat gland cell culture model and by employing
combined pharmacological and molecular approaches, we
provide the first evidence that endocannabinoids markedly
suppress cellular proliferation, induce chiefly apoptosis-
driven cell death, and alter expression/production of various
intracellular proteins (e.g., cytokeratins (CKs)) and lipids in
human sweat gland epithelial cells.
RESULTS
Endocannabinoids inhibit growth and induce chiefly apoptosis-
driven cellular death in NCL-SG3 cells
Using colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) and fluorimetric CyQuant
assays, we found that both AEA and 2-AG dose-dependently
suppressed the viable cell number and proliferation of NCL-
SG3 cells (Figure 1a and b). To define whether this effect was
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Figure 1. Endocannabinoids modulate cell growth and survival of NCL-SG3 cells. NCL-SG3 cells were treated with endocannabinoids (N-arachidonoylethanolamine
(AEA), 2-arachidonoylglycerol (2-AG)) for 48 hours. (a) Determination of cell viability by colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) cell viability assay. (b) Determination of proliferation by fluorimetric CyQuant assay. Quantitative measurement of apoptosis by
(c) fluorimetric DilC1(5) apoptosis assay reflecting mitochondrial membrane potential and (d) fluorimetric poly-caspase apoptosis assay reflecting activation of
pro-apoptotic caspases. Quantitative measurement of necrosis by (e) glucose-6-phosphate-dehydrogenase (G6PD) release assay and (f) Sytox Green assay. Data
(mean±SEM) are expressed as a percentage of the mean value (defined as 100%, dotted line) of the vehicle-treated control group. *Significant (Po0.05)
differences compared with the control group; n¼ 4 in each group. Three to four additional experiments yielded similar results.
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due to the induction of cell death (apoptosis and/or necrosis),
a series of functional assays was performed. As measured by
quantitative fluorimetric determinations, both endocannabi-
noids significantly decreased mitochondrial membrane po-
tential (reflecting mitochondrial disturbance) (Figure 1c) and
induced the activation of pro-apoptotic caspases (Figure 1d),
hallmarks of apoptosis (Green and Reed, 1998; Susin et al.,
1998; To´th et al., 2011). In addition, higher concentrations
of 2-AG significantly increased the release of glucose-6-
phosphate-dehydrogenase (Figure 1e) and Sytox Green
accumulation to the cells (Figure 1f), two complementary
indicators of necrosis/cytotoxicity. (Intriguingly, AEA did not
induce necrosis.) These findings suggested that the endocan-
nabinoids suppressed cellular growth and induced chiefly
apoptosis-driven cell death of human sweat gland cells.
Endocannabinoids markedly alter expressions of certain CKs
and other cytoskeleton proteins involved in cutaneous
differentiation
In most epithelial cells, the cessation of proliferation and the
induction of apoptosis are accompanied by the onset of the
differentiation program of the cells (Candi et al., 2005; Proksch
et al., 2008). Expressions of various intermediate filament CKs
as well as of other cytoskeleton proteins (e.g., involucrin,
filaggrin, loricrin), which were shown to be involved in
differentiation of certain skin cells (e.g., epidermal and hair
follicle keratinocytes), have previously been described on
human eccrine sweat gland epithelium (Ohnishi and Wata-
nabe, 1999; Langbein et al., 2005; Tharakan et al., 2010). Yet,
the exact details of the differentiation process have not been
fully elucidated in cultured sweat gland epithelial cells.
Therefore, we first analyzed the expression of various
epithelial ‘‘differentiation markers’’ such as CKs (CK1, 7, 8,
10, 14, 18, and 19) (Candi et al., 2005; Moll et al., 2008), as
well as of involucrin, filaggrin, and loricrin, in NCL-SG3 cells.
We could not detect the expression of the epidermal
differentiation markers CK1 and 10 (data not shown), whereas
all other molecules were identified (Figure 2). Of great
importance, however, we found that expressions of these
markers differentially altered in parallel with the age of the
cultures. Namely, while levels of CK7, 14, 18, and 19 were
highest in the pre-confluent, highly proliferating cultures
(Figure 2a), expressions of CK8, involucrin, filaggrin, and
loricrin were predominant in the post-confluent, and hence
growth-arrested (and presumably more differentiated) ones
(Figure 2b). It appears, therefore, that expression profiles of
these molecules in NCL-SG3 sweat gland cells, in part similar
to those described, e.g., in cultured epidermal keratinocytes
(Papp et al., 2003, 2004; Candi et al., 2005; Langbein et al.,
2005; Moll et al., 2008), are strongly affected by the growth
rate (i.e., proliferation vs. growth arrest) of the cells.
We then investigated the effects of endocannabinoids. Pre-
confluent (30–40%) NCL-SG3 cells were treated with AEA
and 2-AG (10 mM each) for 48 hours and the levels of the
above markers were analyzed by quantitative ‘‘real-time’’
PCR (Q-PCR). As seen in Figure 2c and d, both endocanna-
binoids significantly (yet differentially) elevated the expres-
sions of the ‘‘post-confluent’’ markers, i.e., CK8, involucrin,
filaggrin, and loricrin. In addition, levels of some of the
markers of the highly proliferating pre-confluent cells, i.e.,
CK7 by 2-AG and CK14 by both AEA and 2-AG, were
markedly suppressed by endocannabinoid treatment.
Endocannabinoids stimulate lipid synthesis in NCL-SG3 cells
Another key function of sweat gland cells is to secrete various
substances. As we have previously shown that endocanna-
binoids markedly induced lipid synthesis in cultured human
sebocytes (Dobrosi et al., 2008), and furthermore, as sweat
gland epithelial cells were shown to synthesize a wide array
of lipids (Takemura et al., 1989), we also assessed whether
endocannabinoids modulate the lipid synthesis of NCL-SG3
cells. As measured by semiquantitative Oil Red-O histo-
chemistry and by quantitative Nile Red-based fluorimetry,
both endocannabinoids (as early as after 24 hours treatment)
markedly and dose-dependently elevated neutral (but not
polar) lipid synthesis of the cells (Figure 2e and f). As
neutral lipids reflect intracellularly accumulated ‘‘de novo’’
synthesized ones, our data argue that endocannabinoids
(besides modulating cell growth, survival, and expressions
of various cytoskeleton proteins) may exert a profound
role in the regulation of secretory activity of human eccrine
sweat gland cells by modifying the composition of the
produced sweat.
Cellular effects of endocannabinoids are not mediated by CB1
or CB2 expressed on NCL-SG3 cells
We then investigated the putative involvement of certain
receptor-mediated signal-transduction systems in mediating
the cellular actions of endocannabinoids. Conforming pre-
vious data (Stander et al., 2005), we first identified the
expressions of both metabotropic CB subtypes (CB1, CB2) on
sweat gland–derived cells using western blot (Figure 3a) and
immunocytochemistry (data not shown) techniques. In
addition, transcription of genes encoding the above proteins
was demonstrated by reverse-transcriptase–PCR (data not
shown) and by Q-PCR (Figure 3b). During the above analysis,
we also observed that the expression of CB1 and CB2
markedly altered in parallel with the culturing of the cells
(Figure 3a and b). Specifically, the level of CB1 monotonously
increased during culturing and reached its maximum in the
post-confluent states. In contrast, the expression of CB2 was
the highest in the pre-confluent cultures, whereas its level
markedly decreased with reaching confluence of the cells.
These data further suggested that the cannabinoids might play
a role in the regulation of growth (and most probably of
differentiation) of the human sweat gland–derived cells.
To assess the roles of the CB receptors, we have employed
various antagonists and the RNA interference (RNAi) techni-
ques. In these experiments, to equally assess changes in
cellular growth, survival, and secretory activities, we
determined cellular viability/proliferation (MTT assay) and
lipid production (Nile Red fluorimetry) of NCL-SG3 cells.
First, various inhibitors of CB subtypes (AM251 for CB1,
AM630 for CB2) were employed. These inhibitors could not
modify the actions of the endocannabinoids, namely both
AEA and 2-AG were still able to suppress cellular viability
www.jidonline.org 1969
G Czifra et al.
Endocannabinoids Inhibit Growth of Human Sweat Gland Cells
and stimulate lipid synthesis in the presence of either
antagonist (Figure 4a and b).
As the pharmacological natures of AM251 and AM630
(i.e., also acting as inverse agonists) (Pertwee et al., 2010)
may compromise their specificities on the CBs, a series of
RNAi experiments against the CBs were carried out in
accordance with the optimized techniques developed in
our previous studies (Dobrosi et al., 2008; To´th et al., 2009,
2011). Western blot analysis (Supplementary Figure S1
online) as well as Q-PCR determination (data not shown)
revealed that expressions of both CB1 and CB2 were
significantly and specifically ‘‘knocked down’’ at day 3 after
transfection by two out of three RNAi probes employed.
However, this phenomenon was reversible as we observed a
‘‘return’’ of their expression at day 4. Scrambled RNAi probes
had no effect on the expression of either CB1 or CB2.
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Figure 2. Endocannabinoids modulate expressions of cytoskeleton proteins and lipid synthesis of NCL-SG3 cells. (a, b) Quantitative ‘‘real-time’’ PCR
(Q-PCR) analysis of various cytokeratins (CK7, 8, 14, 18, 19), involucrin (INV), filaggrin (FIL), and loricrin (LOR) on NCL-SG3 cells at various
confluences. PC1–3, 1–3 days at post-confluence. (c, d) Q-PCR analysis of the above ‘‘differentiation markers’’ after treating NCL-SG3 cells with (c) 10mM
N-arachidonoylethanolamine (AEA) or (d) 2-arachidonoylglycerol (2-AG) for 48 hours. (e) Oil-Red O labeling after treating the cells by 10mM AEA or 2-AG
for 24 hours. Arrows point to the relevant histochemical products. Bar¼ 10mm. (f) Quantitative measurement of intracellular lipids as assessed by Nile
Red labeling, followed by fluorimetric image plate reader (FLIPR) measurement. Neutral lipids indicate intracellular lipids. Data (mean±SEM) are expressed
as a percentage of the mean value (defined as 100%, dotted line) of the vehicle-treated control group. *Significant (Po0.05) differences compared with the
control group; n¼ 4 in each group. Three to four additional experiments yielded similar results.
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We then investigated the effects of endocannabinoids
on NCL-SG3 cells with ‘‘silenced’’ CB1 or CB2. Of great
importance, in perfect agreement with the above pharmaco-
logical data, the molecular ‘‘knockdown’’ of CB1 or CB2
could not prevent the growth-inhibitory and differentiation-
promoting cellular actions of AEA and 2-AG, namely both
endocannabinoids were able to suppress cellular viability
and induce lipid production (Figure 4c and d). Therefore,
these results, in line with the above data obtained with the
antagonists, collectively argue for the fact that CB1- or CB2-
coupled intracellular signaling mechanisms most probably do
not participate in mediating the effects of endocannabinoids
on human sweat gland epithelial cells.
Cellular effects of endocannabinoids are not mediated by TRP
channels expressed on NCL-SG3 cells
Recent intriguing data from our laboratory and from others,
however, suggest that cannabinoid compounds, besides CB1
or CB2, may also target other molecules (Pertwee et al., 2010).
Among these, certain transient receptor potential (TRP) ion
channels were implicated as ‘‘ionotropic CB receptors’’
(Zygmunt et al., 1999; Di Marzo et al., 1998, 2001; Akopian
et al., 2009). These molecules, which function as highly Ca2þ -
permeable ion channels, are the heat-sensitive TRPV1, TRPV2,
TRPV3, and TRPV4, as well as the cold-activated TRPM8 and
TRPA1 (Akopian et al., 2009; Vriens et al., 2009; Di Marzo
and De Petrocellis, 2010; Pertwee et al., 2010). Hence, in the
next phase of our experiments, we investigated the possible
involvement of these molecules.
We first defined the expression profile of TRP channels on
NCL-SG3 cells. As revealed by Q-PCR analysis, human sweat
gland epithelial cells express all thermosensitive TRPV
channels (Supplementary Figure S2a online). However, we
could not detect the expression of cold-sensitive TRPM8 and
TRPA1 (data not shown).
We then investigated whether the TRP channel–mediated
Ca2þ influx to NCL-SG3 cells is involved in the action of
cannabinoids. Using fluorimetric image plate reader (FLIPR)-
based Ca2þ imaging, we found that endocannabinoids (tested
up to 50mM concentration) did not modify the intracellular
Ca2þ concentration in NCL-SG3 cells (data not shown).
In addition, we also observed that neither the ‘‘universal’’ TRP
channel antagonists Ruthenium Red nor the suppression of
extracellular Ca2þ concentration affected the cellular effects
of endocannabinoids to suppress cellular growth and to
induce lipid synthesis (Supplementary Figure S2b and c
online). These findings collectively suggest that TRP channels
are most probably not involved in mediating the actions of
cannabinoids in human sweat gland epithelial cells.
Endocannabinoids selectively stimulate the MAPK pathway in
NCL-SG3 cells
Although we failed to identify surface membrane receptor/
channel coupled mechanisms, we also aimed at
identifying putative endocannabinoid-activated intracellular
signaling pathways. Cannabinoids were shown to induce
various signal-transduction mechanisms, such as e.g., the
mitogen-activated protein kinase (MAPK), protein kinase
C isoenzymes, phosphatidylinositide 3-kinase (Howlett,
2005; Pacher et al. 2006); hence, we investigated the
involvement of these mechanisms.
Using various pharmacological tools, we found that
the general protein kinase C inhibitor GF109203X and the
phosphatidylinositide 3-kinase inhibitor Wortmannin did not
affect the growth-inhibitory and lipid synthesis-promoting
action of the endocannabinoids (Figure 5a and b).
However, of great importance, the MAPK inhibitor
PD098059 markedly (almost completely) prevented the
effects of both AEA and 2-AG. Furthermore, the endocanna-
binoids also induced the transient phosphorylation of the
MAPK Erk1/2 (p42/44) (Figure 5c), which effect was
also abrogated by the application of the aforementioned
antagonist (Figure 5d). These findings collectively argued for
the crucial involvement of the MAPK pathway in mediating
the actions of endocannabinoids in human sweat gland
epithelial cells.
DISCUSSION
In this study, we present early evidence that prototypic
endocannabinoids inhibit proliferation, induce cell death,
and upregulate secretory activity (lipid synthesis) in cultured
human eccrine sweat gland epithelial cells. These data
support the concept that human sweat glands may also
function as novel targets for endocannabinoids, as
emerging members of the skin neuroendocrine regulatory
circuits (Slominski and Wortsman, 2000; Slominski et al.,
2008).
In the course of our experiments, a key goal was to identify
how endocannabinoids affect the differentiation process of
the sweat gland cells. However, as we have detailed above,
the exact ‘‘differentiation marker pattern’’ of cultured sweat
gland epithelial cells is not fully known. Therefore, we have
investigated the expressions of those cytoskeleton proteins
(e.g., various CKs, involucrin, filaggrin, loricrin), which, on
the one hand, were shown to be expressed in human sweat
glands, and, on the other hand, were found to be involved in
differentiation of certain skin cells such as, e.g., epidermal
and hair follicle keratinocytes (Candi et al., 2005; Langbein
et al., 2005). Our experiments resulted in several findings,
which to our knowledge is previously unreported: (i) This is
the first demonstration that, to our best knowledge, shows
that levels of these molecules in cultured human sweat gland
epithelial cells are strongly affected by the growth rate (i.e.,
proliferation vs. high cell density–induced growth arrest) of
the cells. (ii) Moreover, we have also found that expression
patterns of some of these markers were very similar to those
described (by us and others) in human epidermal keratino-
cytes (Papp et al., 2003, 2004; Candi et al., 2005; Langbein
et al., 2005; Moll et al., 2008). Namely, in both cell types,
highest levels of the ‘‘differentiation markers’’ involucrin,
filaggrin, and loricrin were detected in the post-confluent
(hence more differentiated) cultures. Nevertheless, it should
also be noted that the cytoskeleton protein profile of sweat
gland cells, by far, was not identical to those of epidermal
keratinocytes as, e.g., expressions of the ‘‘classical’’ epider-
mal markers CK1 and 10 were not detected in cultured
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sweat gland cells. (iii) Of further importance, we have also
shown that endocannabinoids upregulated the expression of
the above ‘‘post-confluent’’ markers (i.e., involucrin, filag-
grin, and loricrin), whereas suppressed expressions of some of
those cytoskeleton proteins that were expressed at high levels
in the pre-confluent (hence greatly proliferating) cultures.
Taken together, these findings collectively argue that
endocannabinoids not only inhibit cell growth and induce
cell death, but may also promote the differentiation process
in the human sweat gland epithelium.
We also wished to uncover the signaling pathways that
were involved in mediating the cellular actions of endocan-
nabinoids. Quite unexpectedly, we were unable to find
evidence for the involvement of the ‘‘classical’’ metabotropic
CB1 and CB2 receptors (lack of effects of CB1 or CB2
antagonists or RNAi-mediated silencing of these receptors),
or the ‘‘ionotropic CB receptor’’ TRP channels (lack
of elevation of intracellular Ca2þ concentration upon
endocannabinoid challenge) expressed by these cells.
Although these observations suggested a CB1/CB2/TRP-
independent cellular action of the endocannabinoids—
similar to those seen on various cell types, including
e.g., leukocytes, endothelial cells, etc. (Rockwell et al.,
2006; McCollum et al., 2007)—we have intriguingly found
that both AEA and 2-AG selectively stimulated the MAPK
pathway (but not the phosphatidylinositide 3-kinase and
protein kinase C signal-transduction mechanisms). As the
MAPKs are most often activated by receptor-coupled
processes, further studies are now invited to define the exact
intracellular signaling of endocannabinoids in human sweat
gland cells.
Comparison of the above findings with our previously
published data obtained on other human skin adnexal
structures revealed another exciting feature of the cutaneous
effects of cannabinoids. Namely, our presentations that
endocannabinoids (i) inhibit human hair growth and
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Figure 5. Effects of endocannabinoids are mediated by the mitogen-activated protein kinase (MAPK) pathway on NCL-SG3 cells. Cells were treated with
N-arachidonoylethanolamine (AEA) (20 mM), 2-arachidonoylglycerol (2-AG) (20 mM), GF109203X (1 mM, GF), Wortmannin (0.5 mM, Wor), PD098059 (20mM,
PD), or combinations. (a) MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) cellular viability/proliferation assay performed after 48 hours.
(b) Quantitative assessment of neutral lipids by Nile Red labeling, followed by fluorimetric image plate reader (FLIPR) measurement after 24 hours. Data
(mean±SEM) are expressed as a percentage of the mean value (defined as 100%, dotted line) of the vehicle-treated control group. *Significant (Po0.05)
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induce apoptosis by activating CB1 (Telek et al., 2007); (ii)
promote lipid synthesis and apoptosis in human sebaceous
gland–derived sebocytes via CB2-mediated signaling (Dobrosi
et al., 2008); (iii) inhibit proliferation, induce cell death, and
stimulate lipid synthesis and differentiation of human sweat
gland epithelial cells by activating non-CB1/CB2-coupled
signal-transduction pathways; and (iv) highlight the existence
of cell type-specific and (most probably) receptor-selective
regulatory endocannabinoid mechanisms in the human skin
appendages.
Of further importance, sweat gland epithelial cells
apparently are not only targets but sources of endocannabi-
noids. Indeed, mass spectrometry analysis revealed that
NCL-SG3 sweat gland cells produce the prototypic endo-
cannabinoids AEA and 2-AG. However, the concentrations of
the endocannabinoids determined in NCL-SG3 cells (AEA,
15 fmol per 106 cells; 2-AG, 0.2 pmol per 106 cells) were
much less than those found in other human cultures skin cells
(e.g., AEA, 160 fmol per 106 cells; 2-AG, 4.2 pmol per 106
cells in human SZ95 sebocytes) (Telek et al., 2007; Dobrosi
et al., 2008). In addition, we were also able to identify the
expression of those enzymes that are involved in the synthesis
(NAPE-PLD, N-acylphosphatidylethanolamine-hydrolyzing
phospholipase D; DAGL, diacylglycerol lipase-a and -b)
and degradation (FAAH, fatty acid amid hydrolase; MAGL,
monoacylglycerol lipase) of the endocannabinoids (Supple-
mentary Figure S3 online). Interestingly, similar to CB1 and
CB2 receptors (Figure 3), we also detected marked fluctua-
tions in the expressions of the elements of the ECS further
suggesting the role of the ECS in the regulation of growth (and
most probably of differentiation) of the human sweat
gland–derived cells. Finally, by performing immunohisto-
chemical labeling on human skin sections, we were able to
identify the elements of the ECS on eccrine sweat glands
in situ (Supplementary Figure S4 online), which findings
perfectly complement the above PCR data obtained on NCL-
SG3 cells.
Evidently, further explorative research efforts are needed
to define whether alterations in the activities of the above
enzymes can modify the endocannabinoid production (hence
the endocannabinoid ‘‘tone’’) in the human sweat glands in
situ. Nevertheless, our findings now warrant proof-of-
principle clinical studies to test the therapeutic value of
cutaneous ECS-targeted approaches in the clinical manage-
ment of multitude of human skin diseases. Specifically, based
on this preclinical data in human sweat gland model cell
cultures, it is envisaged that agents increasing the cutaneous
endocannabinoid ‘‘tone’’ (such as employing endocannabi-
noids or molecules that upregulate the production of
endocannabinoids by, e.g., stimulating their synthesis of
inhibiting their degradation) (Di Marzo, 2008; Bı´ro´ et al.,
2009) may be successfully applied in certain sweat gland
disorders (e.g., benign or malignant tumors) characterized by
unwanted cell growth—similar to those we have previously
suggested for the management of various growth and
inflammatory conditions of the human pilosebaceous unit
(e.g., hair growth problems, acne vulgaris) (reviewed in Bı´ro´
et al., 2009).
MATERIALS AND METHODS
Materials
Throughout the experiments, the following agents were used: AEA,
2-AG (Cayman, Ann Arbor, MI); AM251, GF109203X, Ruthenium
Red (Sigma-Aldrich, St Louis, MO); AM630 (Tocris, Ellisville, MO);
and PD098059, Wortmannin (Calbiochem, Nottingham, UK).
Cell culturing
Human eccrine sweat gland–derived NCL-SG3 epithelial cells were
cultured in William’s Medium E medium (Invitrogen, Paisley, UK)
supplemented with 5% fetal bovine serum, 10 mg ml1 insulin–-
transferrin–selenium mixture, 20 ng ml1 epidermal growth factor (all
from Invitrogen), and 2 mM L-glutamine, 10 ng ml1 hydrocortisone,
and antibiotic mixture (all from Sigma-Aldrich).
Western blotting
Cell lysates were subjected to SDS-PAGE (8% gels were loaded
with 30 mg protein per lane), transferred to BioBond nitrocellulose
membranes (Whatman, Maidstone, UK), and then probed with the
rabbit primary antibodies against CB1 and CB2 (both 1:200). A
horseradish peroxidase-conjugated goat anti-rabbit IgG antibody
(1:1,000; Bio-Rad, Hercules, CA) was used as a secondary
antibody, and the immunoreactive bands were visualized by a
SuperSignal West Pico Chemiluminescent Substrate-enhanced
chemiluminescence kit (Pierce, Rockford, IL) using LAS-3000
Intelligent Dark Box (Fuji, Tokyo, Japan). To assess equal loading,
membranes were re-probed with an anti-cytochrome C antibody
(1:50; Santa Cruz, Santa Cruz, CA) and visualized as described
above. Where appropriate, immunoblots were subjected to
densitometric analysis using the Image Pro Plus 4.5.0 software
(Media Cybernetics, Silver Spring, MD) (Go¨nczi et al., 2008;
Szegedi et al., 2009).
Immunocytochemistry
Cells were fixed in acetone, permeabilized by 0.1% Triton X-100
(Sigma-Aldrich), and then incubated with the above primary anti-
bodies against CB1 or CB2 (1:200 dilution, Cayman). For fluores-
cence staining, slides were then incubated with FITC-conjugated
secondary antibodies (dilution 1:200) (Bodo´ et al., 2005; Dobrosi
et al., 2008; To´th et al., 2009).
Quantitative real-time PCR
Q-PCR was performed on an ABI Prism 7000 sequence detection
system (Applied Biosystems, Foster City, CA) using the 50 nuclease
assay as detailed in our previous reports (Dobrosi et al., 2008; To´th
et al., 2009, 2011). PCR amplification was performed by using
TaqMan primers and probes (Applied Biosystems) (see Supplemen-
tary data online for Assay IDs).
Determination of viable cell numbers and proliferation
The number of viable cells (hence the rate of proliferation)
was determined by measuring the conversion of the tetrazolium salt
MTT (Sigma-Aldrich) to formazan by mitochondrial dehydrogenases.
In addition, proliferation was also assessed by the CyQuant
fluorimetric Cell Proliferation Assay Kit (Invitrogen) according to
the manufacturer’s protocol (Bodo´ et al., 2005; Kiss et al., 2008;
Szegedi et al., 2009) (see Supplementary data online for further
details).
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Determination of apoptosis
A decrease in the mitochondrial membrane potential is one of the
earliest markers of apoptosis. Mitochondrial membrane potential of
NCL-SG3 cells was determined using a MitoProbe DiIC1(5) Assay Kit
(Invitrogen), where the decrease in fluorescence intensity reflects
apoptosis. In addition, apoptosis was also determined by fluorimetric
measurement of activation of pro-apoptotic caspases using a Poly-
Caspases Detection Kit (Invitrogen) (Dobrosi et al., 2008; To´th et al.,
2009, 2011) (see Supplementary data online for further details).
Determination of cytotoxicity (necrosis)
Necrotic cell death was determined by measuring the glucose-6-
phosphate-dehydrogenase (G6PD) release (G6PD Release Assay Kit;
Invitrogen). Moreover, as the activity of the glucose-6-phosphate-
dehydrogenase released from necrotic cells decreases over
24–36 hours, the cytotoxic effects of long-term treatment protocols
were assessed by the fluorimetric determination of Sytox Green
accumulation to the nuclei of necrotic cells with ruptured plasma
membranes (Invitrogen) (To´th et al., 2009, 2011) (see Supplementary
data online for further details).
Determination of intracellular lipids
For semiquantitative detection of cellular lipids, cells were fixed in
4% paraformaldehyde, washed in 60% isopropanol (both Sigma-
Aldrich), and stained in freshly prepared Oil Red O solution (in 60%
isopropanol) (Sigma-Aldrich). Nuclei were counterstained with
Mayer’s hematoxylin (Sigma-Aldrich) and coverslips were mounted
in mounting medium (DAKO, Glostrup, Denmark). In addition, for
quantitative measurement of lipid content, a Nile Red (Sigma-
Aldrich) fluorimetric method was employed as described before
(Wro´bel et al., 2003; Alestas et al., 2006; Dobrosi et al., 2008; To´th
et al., 2009) (see Supplementary data online for further details).
RNA interference
NCL-SG3 cells at 50–70% confluence were transfected with specific
Stealth RNAi oligonucleotides (40 nM; all from Invitrogen) against
CB1 (ID No. HSS102082) or CB2 (ID No. HSS102087) using
Lipofectamine 2000 Transfection Reagent (Invitrogen). For controls,
RNAi Negative Control Duplexes (scrambled RNAi; Invitrogen) were
employed. The efficacy of RNAi-driven ‘‘knockdown’’ was daily
evaluated by Q-PCR and western blotting for 4 days (see
Supplementary Figure S1 online and Supplementary data online
for further details).
Ca2þ imaging
Changes in intracellular Ca2þ concentration upon drug applications
were detected by fluorimetric Ca2þ imaging (Bodo´ et al., 2005;
Go¨nczi et al., 2008; To´th et al., 2009). Cells were seeded in 96-well
black-well/clear-bottom plates (Greiner Bio One, Frickenhausen,
Germany) at a density of 10,000 cells per well and then were
incubated with culturing medium containing the cytoplasmic
calcium indicator 2 mM Fluo-4 AM (Invitrogen) at 37 1C for
40 minutes. The cells were washed four times with and finally
cultured in Hank’s solution containing 1% bovine serum albumin
and 2.5 mM Probenecid (both from Sigma-Aldrich) for 30 minutes at
37 1C. The plates were then placed to a FlexStation II384 FLIPR
(Molecular Devices, San Francisco, CA) and changes in intracellular
Ca2þ concentration (reflected by changes in fluorescence;
lEX¼ 494 nm, lEM¼ 516 nm) induced by various concentrations of
the drugs were recorded in each well (during the measurement,
cells in a given well were exposed to only one given concentration
of the agent).
Statistical analysis
When applicable, data were analyzed using a two-tailed unpaired
t-test and Po0.05 values were regarded as significant differences. In
addition, statistical differences were further verified using one-way
analysis of variance with Bonferroni’s and Dunnett’s post-hoc
probes, resulting in similar results (data not shown).
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